Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

News

$Aptevo Therapeutics(APVO.US)$ Aptevo Therapeutics Announces Advancements In Clinical Programs And One Preclinical Program
Benzinga· 1 min ago
Breast cancer patient who improved from a progressive disease diagnosis to an over nine-month sustained stable disease diagnosis has now successfully transitioned to a higher dose level, accessing the potential for greater clinical benefit in the ALG.APV-527 clinical trial
Cohort 5 dosing imminent, trial more than 50% enrolled
APVO436 Phase 1b/2 dose optimization trial initiation expected 1H 2024
Premier CRO, Prometrika, engaged as partner for dose optimization trial to evaluate APVO436 in frontline AML in combination with venetoclax + azacitidine in venetoclax naïve patients
APVO711 demonstrates its ability to induce tumor killing properties in preclinical studies
APVO711 dual mechanism checkpoint inhibitor with unique precision targeting capabilities progressing towards IND
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
1
+0
4
Translate
Report
3930 Views
Comment
Sign in to post a comment
1774Followers
28Following
21KVisitors
Follow